Innate Pharma (IPHA) Capital Expenditures (2019 - 2025)
Innate Pharma (IPHA) posted quarterly Capital Expenditures of -$159313.6 for Q4 2025, up 64.19% year-on-year from -$97027.4 in Q4 2024, and up 64.19% on a QoQ basis from -$444940.1 in Q4 2024.
Innate Pharma (IPHA) Capital Expenditures (2019 - 2025) Analysis & Trends
Innate Pharma (IPHA) has reported Capital Expenditures for 7 consecutive years, with -$159313.6 the latest figure, recorded in Q4 2025.
- Quarterly Capital Expenditures rose 64.19% year-over-year to -$159313.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$681634.6 (down 29.65% YoY) and the FY2025 annual result came in at $159313.6, down 64.19% from the prior year.
- Capital Expenditures grew to -$159313.6 in Q4 2025 per IPHA's latest filing, from -$444940.1 in the prior quarter.
- Over the last five years, Capital Expenditures for IPHA reached as high as $322041.1 in Q2 2024 and fell as low as -$1.1 million in Q4 2021.
- A 5-year average of -$269315.8 and a median of -$159313.6 in 2025 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures plunged 200.0% — and 2024, when it jumped 9533.33%.
- Year by year, Capital Expenditures stood at -$1.1 million in 2021, then soared by 42.41% to -$608805.5 in 2022, then surged by 34.39% to -$399421.9 in 2023, then fell by 11.4% to -$444940.1 in 2024, then soared by 64.19% to -$159313.6 in 2025.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$159313.6, -$444940.1, and $322041.1 for Q4 2025, Q4 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Innate Pharma | 157.68 Mn | 157.68 Mn | - | -159,313.60 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -159,313.60 |
| Dec 31, 2025 | -159,313.60 |
| Dec 31, 2024 | -444,940.12 |
| Dec 31, 2024 | -444,940.12 |
| Jun 30, 2024 | 322,041.06 |
| Jun 30, 2024 | 322,041.06 |
| Dec 31, 2023 | -399,421.95 |
| Dec 31, 2023 | -399,421.95 |
| Jun 30, 2023 | -3,413.86 |
| Jun 30, 2023 | -3,413.86 |
| Dec 31, 2022 | -608,805.54 |
| Dec 31, 2022 | -608,805.54 |
| Jun 30, 2022 | -1,137.95 |
| Jun 30, 2022 | -1,137.95 |
| Dec 31, 2021 | -1.06 Mn |
| Dec 31, 2021 | -1.06 Mn |
| Jun 30, 2021 | -71,691.12 |
| Jun 30, 2021 | -71,691.12 |
| Dec 31, 2020 | -1.03 Mn |
| Dec 31, 2020 | -1.03 Mn |